Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/69339

Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness
Ruiz de Garibay, Gorka; Herranz, Carmen; Llorente, Alicia; Boni, Jacopo; Serra-Musach, Jordi; Mateo González, Francesca; Aguilar, Helena; Gómez-Baldó, Laia; Petit, Anna; Vidal-Bel, August; Climent, Fina; Hernández-Losa, Javier; Cordero, Álex; González-Suárez, Eva; Sánchez-Mut, José Vicente; Esteller, Manel; Llatjós, Roger; Varela, Mar; López, J.I.; García, N.; Extremera, A.I.; Gumà, Anna; Ortega, R.; Plà, M.J.; Fernández, A.; Pernas, S.; Falo, Catalina; Morilla, Idoia; Campos, Miriam; Gil, M.; Román, A.; Molina-Molina, M.; Ussetti, P.; Laporta, Rosalía; Valenzuela, Claudio; Ancochea, Julio; Xaubet, Antoni; Casanova, Álvaro; Pujana, Miguel Angel
Universitat de Barcelona
Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-ß3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.
Càncer de mama
Metàstasi
Marcadors tumorals
Càncer de pulmó
Breast cancer
Metastasis
Tumor markers
Lung cancer
cc-by (c) Ruiz de Garibay, G. et al., 2015
http://creativecommons.org/licenses/by/3.0/es
Artículo
info:eu-repo/semantics/publishedVersion
Public Library of Science (PLoS)
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Ruiz de Garibay, Gorka; Herranz, Carmen; Llorente, Alicia; Boni, Jacopo; Serra-Musach, Jordi; Mateo González, Francesca; Aguilar, Helena; Gómez-Baldó, Laia; Petit, Anna; Vidal-Bel, August; Climent, Fina; Hernández-Losa, Javier; Cordero, Álex; González-Suárez, Eva; Sánchez-Mut, José Vicente; Esteller, Manel; Llatjós, Roger; Varela, Mar; López, J.I.; García, N.; Extremera, A.I.; Gumà, Anna; Ortega, R.; Plà, M.J.; Fernández, A.; Pernas, S.; Falo, Catalina; Morilla, Idoia; Campos, Miriam; Gil, M.; Román, A.; Molina-Molina, M.; Ussetti, P.; Laporta, Rosalía; Valenzuela, Claudio; Ancochea, Julio; Xaubet, Antoni; Casanova, Álvaro; Pujana, Miguel Angel
Ussetti, P.; Roca Torrent, Josep